Complement-Mediated Mechanisms in Diabetic Kidney Disease

The complement system, a core component of innate immunity, has emerged as a pivotal mediator in the progression of diabetic kidney disease (DKD). In the hyperglycaemic milieu of diabetes, activation of the classical, lectin and alternative pathways generates effector fragments such as C3a and C5a and culminates in the assembly of the membrane attack complex (C5b-9). These fragments act as potent anaphylatoxins and recruit inflammatory cells to glomerular and tubular compartments. Locally synthesized complement components within renal cells amplify tissue injury, driving podocyte dysfunction, basement membrane thickening and mesangial expansion. Downstream effects include up-regulation of pro-fibrotic factors, deposition of extracellular matrix and tubulointerstitial fibrosis. Experimental blockade of key complement receptors has demonstrated preservation of podocyte architecture, attenuation of oxidative stress and mitigation of inflammatory cytokine release. Given the global burden of DKD, targeting complement activation offers a promising avenue to complement glycaemic control and renin–angiotensin blockade, with the potential to slow progression to end-stage renal failure and reduce healthcare costs.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Complement-Mediated Mechanisms in Diabetic Kidney Disease publication trend

The graph below shows the total number of articles in complement-mediated mechanisms in diabetic kidney disease across all publications each year (not limited to Nature Index journals).

Technical terms

Complement system: A cascade of plasma and membrane proteins that defends against pathogens and, when dysregulated, contributes to inflammation and tissue injury.

Anaphylatoxin: Small complement fragments (C3a, C5a) that induce chemotaxis, vasodilation and cytokine release.

Membrane attack complex (C5b-9): The terminal complement assembly that forms pores in cell membranes, leading to cell lysis or sublytic activation.

Podocyte: A specialised epithelial cell in the glomerulus essential for filtration barrier integrity; injury leads to proteinuria.

Tubulointerstitial fibrosis: Accumulation of extracellular matrix in the renal interstitium, resulting in impaired tubular function and chronic scarring.

Extracellular matrix (ECM): A network of proteins and glycoproteins that provides structural support to cells and, when excessive, drives fibrosis.

References

1. C3a Receptor Antagonist Ameliorates Inflammatory and Fibrotic Signals in Type 2 Diabetic Nephropathy by Suppressing the Activation of TGF-β/smad3 and IKBα Pathway. PLOS ONE (2014).
2. C3a receptor blockade protects podocytes from injury in diabetic nephropathy. JCI Insight (2020).
3. The Complement Cascade and Renal Disease. Archivum Immunologiae et Therapiae Experimentalis (2013).
4. The Expression Profile of Complement Components in Podocytes. International Journal of Molecular Sciences (2016).
5. Complement C5 activation promotes type 2 diabetic kidney disease via activating STAT3 pathway and disrupting the gut‐kidney axis. Journal of Cellular and Molecular Medicine (2020).